Literature DB >> 651945

Lidocaine kinetics predicted by indocyanine green clearance.

R A Zito, P R Reid.   

Abstract

To evaluate the importance of hepatic blood flow in lidocaine kinetics, we compared indocyanine green clearance, an estimate of hepatic plasma flow, to lidocaine clearance in 26 patients, half with and half without congestive heart failure, who received a lidocaine infusion for 24 hours as clinically indicated. The results demonstrated that patients with congestive heart failure had significantly higher steady-state lidocaine levels (6.8 +/- 3.6(S.D.) vs. 2.9 +/- 0.9 microgram per milliliter, P less than 0.005) and reduced lidocaine clearance (3.8 +/- 1.4 vs. 10.9 +/- 3.1 ml per minute per kilogram, P less than 0.005) than patients without heart failure. Potentially subtherapeutic or toxic lidocaine levels were found in 10 patients. The regression line (y = 0.3 + 1.07 x) relating clearance of lidocaine to that of indocyanine green was linear (r = 0.95, P less than 0.001). Since indocyanine green clearance can be determined rapidly and noninvasively, it offers the potential of predicting lidocaine dosage requirements with avoidance of toxicity or suboptimum therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 651945     DOI: 10.1056/NEJM197805252982102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Effect of pentoxifylline on liver plasma flow in normal man.

Authors:  A Suren; F E Bauer; B Rosenkranz; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.

Authors:  Yu-Si Chen; Zi-Qi Liu; Rong Chen; Lei Wang; Ling Huang; Xiao Zhu; Tian-Yan Zhou; Wei Lu; Ping Ma
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

Review 6.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 9.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

10.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.